MedPath

UNIVERSITY OF MICHIGAN

UNIVERSITY OF MICHIGAN logo
🇺🇸United States
Ownership
Private
Established
1817-01-01
Employees
10K
Market Cap
-
Website
http://www.umich.edu

Clinical Trials

1.4k

Active:51
Completed:994

Trial Phases

6 Phases

Early Phase 1:17
Phase 1:64
Phase 2:82
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1199 trials with phase data)• Click on a phase to view related trials

Not Applicable
935 (78.0%)
Phase 2
82 (6.8%)
Phase 4
74 (6.2%)
Phase 1
64 (5.3%)
Phase 3
27 (2.3%)
Early Phase 1
17 (1.4%)

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

Not Applicable
Not yet recruiting
Conditions
Blood Loss, Surgical
Blood Loss, Postoperative
Uterine Atony
Interventions
First Posted Date
2025-10-20
Last Posted Date
2025-10-20
Lead Sponsor
University of Michigan
Target Recruit Count
140
Registration Number
NCT07217899
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Passive Robots for Stroke Rehabilitation: A Feasibility Study

Not Applicable
Recruiting
Conditions
Stroke
First Posted Date
2025-10-20
Last Posted Date
2025-10-20
Lead Sponsor
University of Michigan
Target Recruit Count
4
Registration Number
NCT07218276
Locations
🇺🇸

University of Michigan - NeuRRo Lab, Ann Arbor, Michigan, United States

EDUCATE-C: Education on Cirrhosis -- Assessing Text vs Video

Not Applicable
Completed
Conditions
Cirrhosis
First Posted Date
2025-10-15
Last Posted Date
2025-10-15
Lead Sponsor
University of Michigan
Target Recruit Count
218
Registration Number
NCT07216807
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Engineering Whole Health Into Hospital Care - University of Michigan

Not Applicable
Not yet recruiting
Conditions
Whole Health
First Posted Date
2025-10-10
Last Posted Date
2025-10-10
Lead Sponsor
University of Michigan
Target Recruit Count
300
Registration Number
NCT07215117
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic Pain

Not Applicable
Recruiting
Conditions
SLE (Systemic Lupus)
Chronic Pain
First Posted Date
2025-09-29
Last Posted Date
2025-10-10
Lead Sponsor
University of Michigan
Target Recruit Count
15
Registration Number
NCT07196072
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 286
  • Next

News

First-in-Class Monoclonal Antibody Shows Promise Against Sepsis-Induced Immune Dysregulation

Researchers at University of Virginia and University of Michigan developed a humanized monoclonal antibody targeting citrullinated histone H3 to combat sepsis, which kills approximately 11 million people worldwide annually.

University of Michigan Develops At-Home Melanoma Detection Patch Using Microneedle Technology

Researchers at the University of Michigan have developed the ExoPatch, a silicone patch with star-shaped microneedles that can detect melanoma by capturing disease-specific exosomes from skin tissue.

Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

Courage Therapeutics Appoints Giovanni Ferrara as CEO to Advance Melanocortin-Targeted Obesity Treatments

Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.

Epcoritamab Demonstrates Durable 3-Year Remissions in Relapsed/Refractory Large B-Cell Lymphoma

Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.

Mayo Clinic Researchers Discover Drug Treatment to Triple Donor Heart Preservation Time

Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.

DT-109: Novel Glycine-Based Compound Shows Dual Efficacy Against Atherosclerosis and MASH

• University of Michigan researchers have demonstrated that DT-109, a glycine-based tripeptide, significantly reduces atherosclerotic plaque formation in nonhuman primates while inhibiting vascular calcification processes. • The compound, which previously showed efficacy in treating metabolic dysfunction-associated steatotic liver disease (MASH), represents a potential breakthrough as a dual-action therapy addressing both liver dysfunction and cardiovascular complications. • Unlike conventional treatments that primarily lower cholesterol, DT-109 targets underlying inflammatory pathways including NLRP3 inflammasome signaling, potentially addressing root causes of atherosclerosis rather than just managing symptoms.

Breakthrough T1D Invests $2.8 Million to Establish Joint Cardiorenal Center of Excellence for Type 1 Diabetes Research

Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.

Trump Administration Cancels $800 Million in LGBTQ Health Research Funding

The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.

Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals

One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.